Overview
Registering a pharmaceutical product in Egypt requires navigating the Egyptian Drug Authority (EDA) regulatory framework, preparing a comprehensive Common Technical Document (CTD) dossier, and coordinating submissions across multiple departments. This guide walks through the complete process.
Understanding the EDA
The Egyptian Drug Authority is the primary regulatory body responsible for pharmaceutical product approval in Egypt. Established to modernize Egypt's regulatory landscape, the EDA oversees drug registration, post-market surveillance, and pharmacovigilance activities.
Key EDA departments involved in product registration include:
- Central Administration for Pharmaceutical Affairs (CAPA) — handles product registration
- National Organization for Drug Control and Research (NODCAR) — conducts quality testing
- Egyptian Pharmacovigilance Center — monitors post-approval safety
The Registration Process
Step 1: Pre-Submission Assessment
Before submitting a registration application, companies should assess their product against Egyptian market requirements. This includes evaluating whether the active pharmaceutical ingredient (API) is listed in the Egyptian Pharmacopoeia and understanding any specific local requirements for the dosage form.
Step 2: CTD Dossier Preparation
The EDA requires a full CTD dossier organized into five modules:
- Module 1: Administrative information and prescribing information specific to Egypt
- Module 2: Quality overall summary, nonclinical overview, and clinical overview
- Module 3: Quality data (drug substance and drug product specifications)
- Module 4: Nonclinical study reports
- Module 5: Clinical study reports
Egypt increasingly accepts eCTD format for submissions, which can accelerate review timelines.
Step 3: Submission and Review
Once the dossier is complete, it is submitted to the EDA along with product samples for laboratory testing at NODCAR. The review process typically involves:
- Administrative review and document verification
- Scientific evaluation of quality, safety, and efficacy data
- Laboratory testing of submitted samples
- Pricing and reimbursement assessment
- Final approval decision
Step 4: Post-Approval Requirements
After registration, companies must maintain compliance through regular variations for any product changes, periodic safety update reports, and ongoing quality monitoring. The registration must be renewed periodically.
Timeline Expectations
The registration process in Egypt can take anywhere from 12 to 24 months depending on the product type, completeness of the submission, and EDA workload. Working with an experienced local partner can help avoid delays caused by incomplete documentation or regulatory queries.
How Epidis Pharma Can Help
Epidis Pharma provides end-to-end regulatory affairs services for pharmaceutical product registration in Egypt, including CTD dossier preparation, EDA submission management, and ongoing lifecycle support. Our regulatory team maintains direct relationships with EDA departments and deep knowledge of local requirements.
